|
WO2004014881A2
(en)
*
|
2002-08-09 |
2004-02-19 |
Astra Zeneca Ab |
'1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
|
|
US7585881B2
(en)
*
|
2004-02-18 |
2009-09-08 |
Astrazeneca Ab |
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
|
JP2007533743A
(ja)
*
|
2004-04-20 |
2007-11-22 |
メルク エンド カムパニー インコーポレーテッド |
アルツハイマー病治療のためのβ−セクレターゼ阻害薬として有用な１，３，５−置換フェニル誘導体化合物
|
|
JPWO2006080533A1
(ja)
*
|
2005-01-31 |
2008-06-19 |
持田製薬株式会社 |
３−アミノ−１，２，４−トリアゾール誘導体
|
|
UY29796A1
(es)
*
|
2005-09-29 |
2007-04-30 |
Astrazeneca Ab |
Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
|
|
TW200811179A
(en)
*
|
2006-05-05 |
2008-03-01 |
Astrazeneca Ab |
mGluR5 modulators VI
|
|
TW200811157A
(en)
|
2006-05-05 |
2008-03-01 |
Astrazeneca Ab |
mGluR5 modulators I
|
|
TW200808800A
(en)
*
|
2006-05-05 |
2008-02-16 |
Astrazeneca Ab |
MGluR5 modulators V
|
|
CA2657247A1
(en)
*
|
2006-07-28 |
2008-01-31 |
Boehringer Ingelheim International Gmbh |
Compounds which modulate the cb2 receptor
|
|
TW200821305A
(en)
*
|
2006-10-05 |
2008-05-16 |
Astrazeneca Ab |
MGluR5 modulators
|
|
EP2167464B1
(en)
*
|
2007-05-25 |
2014-12-03 |
AbbVie Deutschland GmbH & Co KG |
Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
|
|
JP2010533147A
(ja)
|
2007-07-13 |
2010-10-21 |
アデックス ファルマ エス．エイ． |
代謝調節型グルタミン酸レセプターのモジュレーターとしてのピラゾール誘導体
|
|
BRPI0818448A2
(pt)
*
|
2007-10-19 |
2015-05-12 |
Astrazeneca Ab |
Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou prevenção de um distúrbio madiano pelo receptor mglur5.
|
|
WO2009054786A1
(en)
*
|
2007-10-26 |
2009-04-30 |
Astrazeneca Ab |
1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5
|
|
WO2009054785A1
(en)
*
|
2007-10-26 |
2009-04-30 |
Astrazeneca Ab |
1,2,4-triazole ether derivatives as modulators of mglur5
|
|
CA2704684A1
(en)
*
|
2007-11-07 |
2009-05-14 |
Boehringer Ingelheim International Gmbh |
Compounds which modulate the cb2 receptor
|
|
CA2718166A1
(en)
*
|
2008-03-03 |
2009-09-17 |
Stiefel Laboratories, Inc. |
Processes for preparing enantiomerically pure diol and dioxolane compounds
|
|
EP3782991A1
(en)
|
2008-05-14 |
2021-02-24 |
The Scripps Research Institute |
Novel modulators of sphingosine phosphate receptors
|
|
US8178568B2
(en)
*
|
2008-07-10 |
2012-05-15 |
Boehringer Ingelheim International Gmbh |
Sulfone compounds which modulate the CB2 receptor
|
|
WO2010019100A1
(en)
*
|
2008-08-12 |
2010-02-18 |
Astrazeneca Ab |
A new crystalline form of 4- (5- { (ir) -1- [5- (3- chlorophenyl) isoxazol-3-yl] ethoxy } -4-methyl-4h-l, 2, 4- triazol-3-yl) pyridine
|
|
EP2324019A4
(en)
*
|
2008-08-12 |
2011-10-05 |
Astrazeneca Ab |
CRYSTALLINE FORM OF (5- {(IR) -1- [5- (3-CHLOROPHENYL) ISOXAZOL-3-YL] ETHOXY} -4-METHYL-4H-L, 2, 4-TRIAZOL-3-YL) -PYRIDINE
|
|
CA2737639A1
(en)
|
2008-09-25 |
2010-04-01 |
Boehringer Ingelheim International Gmbh |
Compounds which selectively modulate the cb2 receptor
|
|
EP2379531A1
(en)
*
|
2008-12-18 |
2011-10-26 |
AstraZeneca AB |
Processes for the manufacture of 3-{4-methyl-5- [ (ir) -1- (2- (3-methylphenyl) -2h-tetrazol-5-yl) -ethoxy]-4h- [1,2, 4]triazol-3-yl} -pyridine, 4-methyl-3-methylthio-5- (3- pyridyl)-l,2,4-triazole, and (ir) -1- [2- (3-methylphenyl) -2h- tetrazol-5-yl]ethanol
|
|
US8349852B2
(en)
|
2009-01-13 |
2013-01-08 |
Novartis Ag |
Quinazolinone derivatives useful as vanilloid antagonists
|
|
JP5705748B2
(ja)
|
2009-02-18 |
2015-04-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｂ２受容体を変調する複素環化合物
|
|
WO2010114971A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Sepracor Inc. |
Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
|
|
US20100273805A1
(en)
*
|
2009-04-23 |
2010-10-28 |
Astrazeneca Ab |
Sulphide bridged derivatives as modulators of mglur5 733
|
|
CA2764339A1
(en)
*
|
2009-06-05 |
2010-12-09 |
Oslo University Hospital Hf |
Azole derivatives as wtn pathway inhibitors
|
|
US8299103B2
(en)
*
|
2009-06-15 |
2012-10-30 |
Boehringer Ingelheim International Gmbh |
Compounds which selectively modulate the CB2 receptor
|
|
JP5756800B2
(ja)
|
2009-06-16 |
2015-07-29 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
|
|
WO2011037795A1
(en)
*
|
2009-09-22 |
2011-03-31 |
Boehringer Ingelheim International Gmbh |
Compounds which selectively modulate the cb2 receptor
|
|
MX2012005560A
(es)
*
|
2009-11-13 |
2012-10-05 |
Receptos Inc |
Moduladores selectivos del receptor de esfingosina 1 fosfato y metodos de sintesis quiral.
|
|
PH12012500940B1
(en)
*
|
2009-11-13 |
2018-09-26 |
Receptos Llc |
Selective heterocyclic sphingosine 1 phosphate receptor modulators
|
|
ES2665461T3
(es)
*
|
2009-11-13 |
2018-04-25 |
Celgene International Ii Sàrl |
Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral
|
|
CN101712641B
(zh)
*
|
2009-12-29 |
2013-05-08 |
江苏工业学院 |
一种甲硫基苯甲酸的制备方法
|
|
ES2443578T3
(es)
*
|
2009-12-29 |
2014-02-19 |
Eli Lilly And Company |
Compuestos de tetrahidrotriazolopiridina como potenciadores de receptores selectivos de mGlu5 útiles para el tratamiento de la esquizofrenia
|
|
WO2011088015A1
(en)
|
2010-01-15 |
2011-07-21 |
Boehringer Ingelheim International Gmbh |
Compounds which modulate the cb2 receptor
|
|
AR080056A1
(es)
|
2010-02-01 |
2012-03-07 |
Novartis Ag |
Derivados de ciclohexil-amida como antagonistas de los receptores de crf
|
|
JP2013518085A
(ja)
|
2010-02-01 |
2013-05-20 |
ノバルティス アーゲー |
ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
|
|
JP5748777B2
(ja)
|
2010-02-02 |
2015-07-15 |
ノバルティス アーゲー |
Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
|
|
US8329735B2
(en)
|
2010-03-05 |
2012-12-11 |
Boehringer Ingelheim International Gmbh |
Tetrazole compounds which selectively modulate the CB2 receptor
|
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
|
US9133123B2
(en)
|
2010-04-23 |
2015-09-15 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
|
WO2012012307A1
(en)
|
2010-07-22 |
2012-01-26 |
Boehringer Ingelheim International Gmbh |
Sulfonyl compounds which modulate the cb2 rece
|
|
EP2632900A2
(en)
*
|
2010-10-28 |
2013-09-04 |
Merck Sharp & Dohme Corp. |
Caprolactam mglur5 receptor modulators
|
|
RU2013128448A
(ru)
|
2010-12-08 |
2015-01-20 |
Осло Юниверсити Хоспитал Хф |
Производные триазола в качестве ингибиторов сигнального пути wnt
|
|
DE102010063974B4
(de)
*
|
2010-12-22 |
2021-10-07 |
Thomas Rühl |
Pharmakologische Wirkstoffe und Radiodiagnostika mit 18F-markierter 3-Aryl- oder 3-Heteroaryl-1,2,4-oxadiazoleinheit und Verfahren zu deren Herstellung
|
|
AU2012232711B2
(en)
|
2011-03-18 |
2016-04-28 |
Novartis Ag |
Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
|
|
US8759380B2
(en)
*
|
2011-04-22 |
2014-06-24 |
Cytokinetics, Inc. |
Certain heterocycles, compositions thereof, and methods for their use
|
|
US9481659B2
(en)
|
2011-05-13 |
2016-11-01 |
Celgene International Ii Sàrl |
Selective heterocyclic sphingosine 1 phosphate receptor modulators
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
US9199975B2
(en)
|
2011-09-30 |
2015-12-01 |
Asana Biosciences, Llc |
Biaryl imidazole derivatives for regulating CYP17
|
|
EP2803668A1
(en)
|
2013-05-17 |
2014-11-19 |
Boehringer Ingelheim International Gmbh |
Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
|
|
HUE038169T2
(hu)
|
2013-09-06 |
2018-09-28 |
Aurigene Discovery Tech Ltd |
1,2,4-Oxadiazol származékok mint immunomodulátorok
|
|
JP6858129B2
(ja)
*
|
2015-03-05 |
2021-04-14 |
バイエル・クロップサイエンス・アクチェンゲゼルシャフト |
置換されたフェニルイソオキサゾリン誘導体の製造方法
|
|
KR102894264B1
(ko)
|
2015-03-10 |
2025-12-02 |
오리진 온콜로지 리미티드 |
면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
|
|
BR112017019304A2
(pt)
*
|
2015-03-10 |
2018-05-08 |
Aurigene Discovery Technologies Limited |
compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
|
|
CA2968836C
(en)
|
2016-06-13 |
2025-09-02 |
Gilead Sciences, Inc. |
FXR MODULATING COMPOUNDS (NR1H4)
|
|
NZ748641A
(en)
|
2016-06-13 |
2020-04-24 |
Gilead Sciences Inc |
Fxr (nr1h4) modulating compounds
|
|
SI4122464T1
(sl)
|
2017-03-28 |
2024-07-31 |
Gilead Sciences, Inc. |
Terapevtske kombinacije za zdravljenje bolezni jeter
|
|
WO2019061324A1
(en)
|
2017-09-29 |
2019-04-04 |
Curis Inc. |
CRYSTALLINE FORMS OF IMMUNOMODULATORS
|
|
AU2018346597B2
(en)
|
2017-10-06 |
2023-07-13 |
Forma Therapeutics, Inc. |
Inhibiting Ubiquitin Specific Peptidase 30
|
|
EP3694841A1
(en)
|
2017-10-11 |
2020-08-19 |
Aurigene Discovery Technologies Limited |
Crystalline forms of 3-substituted 1,2,4-oxadiazole
|
|
MY206121A
(en)
|
2017-11-03 |
2024-11-29 |
Aurigene Discovery Tech Ltd |
Dual inhibitors of tim-3 and pd-1 pathways
|
|
AU2018360389B2
(en)
|
2017-11-06 |
2024-09-19 |
Aurigene Oncology Limited |
Conjoint therapies for immunomodulation
|
|
US11103468B2
(en)
|
2017-11-16 |
2021-08-31 |
Montdorex Inc. |
Mono- and di-amidine endo-exonuclease inhibitors and methods for inhibiting endo-exonuclease activity
|
|
JP7449242B2
(ja)
|
2018-05-17 |
2024-03-13 |
フォーマ セラピューティクス，インコーポレイテッド |
ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
|
|
JP7530889B2
(ja)
|
2018-10-05 |
2024-08-08 |
フォーマ セラピューティクス，インコーポレイテッド |
ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン
|
|
PT3911647T
(pt)
|
2019-01-15 |
2024-03-04 |
Gilead Sciences Inc |
Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
|
|
JP2022519906A
(ja)
|
2019-02-19 |
2022-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｆｘｒアゴニストの固体形態
|
|
CA3139063A1
(en)
*
|
2019-05-03 |
2020-11-12 |
Praxis Precision Medicines, Inc. |
Kcnt1 inhibitors and methods of use
|
|
KR20220097405A
(ko)
*
|
2019-11-05 |
2022-07-07 |
클라에스 툴린 |
포유동물에서의 혹사의 예방 및/또는 치료에 사용하기 위한 4-[5-[(rac)-1-[5-(3-클로로페닐)-3-이속사졸일]에톡시]-4-메틸-4H-1,2,4-트리아졸-3-일]피리딘
|
|
WO2021142006A1
(en)
*
|
2020-01-07 |
2021-07-15 |
Disarm Therapeutics, Inc. |
Inhibitors of sarm1
|
|
CA3169779A1
(en)
|
2020-02-28 |
2021-09-02 |
Andrew Mark Griffin |
Kcnt1 inhibitors and methods of use
|
|
TWI904906B
(zh)
|
2020-08-24 |
2025-11-11 |
美商達薩瑪治療公司 |
Sarm1之抑制劑
|
|
WO2022231872A1
(en)
*
|
2021-04-29 |
2022-11-03 |
Praxis Precision Medicines, Inc. |
Kcnt1 inhibitors and methods of use
|
|
PL4514782T3
(pl)
|
2022-05-19 |
2026-02-23 |
Astrazeneca Ab |
Związki amidoheteroaromatyczne przydatne w leczeniu chorób wątroby
|
|
WO2025212948A1
(en)
*
|
2024-04-04 |
2025-10-09 |
University Of Iowa Research Foundation |
Therapeutic compounds and methods
|